Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG40932

EIF2AK2 Knockout CAL27 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Oral cavity (tongue)

  • Disease:

    Adenosquamous carcinoma

EIF2AK2 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in the human tongue squamous cell carcinoma line CAL-27. This model disrupts the dsRNA-activated kinase PKR, which phosphorylates eIF2?? to inhibit translation and triggers NF-??B, p38 MAPK, and caspase-driven apoptosis. Ideal for studying PKR??s role in oral cancer stress responses, antiviral signaling, and drug sensitivity, this polyclonal knockout enables phospho-eIF2?? Western blotting, interferon-stimulated gene analysis, and apoptosis assays without monoclonal selection artifacts. Contact Ascent Research for further details.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    CAL-27

    Sex of Donor

    Male

    Age

    56 years

    Derived From Site

    In situ; Tongue

    Gene Name

    EIF2AK2

    Gene Identifier

    NCBI Gene ID 5610

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    DMEM

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

This product provides a CRISPR/Cas9-edited polyclonal knockout cell population of CAL-27 cells with targeted disruption of the EIF2AK2 gene. The pooled cells harbor a heterogeneous spectrum of gene disruptions achieved through non-homologous end joining-based repair, offering a loss-of-function model system without single-cell clonal isolation. This polyclonal format preserves broader genetic diversity while eliminating functional EIF2AK2 protein expression, enabling robust investigation of PKR-dependent phenotypes in a physiologically relevant oral cancer background.

CAL-27 is a well-characterized human tongue squamous cell carcinoma cell line with epithelial morphology and adherent growth properties. Derived from a poorly differentiated oral squamous cell carcinoma, CAL-27 serves as a standard in vitro model for studying oral cancer biology, epithelial-to-mesenchymal transition, invasion, and therapeutic responses. The tongue origin makes this line particularly relevant for investigating PKR function in cancers influenced by viral co-factors and inflammatory microenvironments.

EIF2AK2 encodes the double-stranded RNA (dsRNA)-activated serine/threonine kinase PKR, a critical regulator of translational control and innate immunity. Upon detection of viral dsRNA or endogenous stress signals such as interferon-alpha/beta, tumor necrosis factor-alpha, ER stress, and oxidative stress, PKR undergoes autophosphorylation and phosphorylates its primary substrate, eIF2?? (EIF2S1). This phosphorylation inhibits eIF2B-mediated guanine nucleotide exchange, leading to global translation attenuation and concomitant activation of integrated stress response pathways. PKR signaling converges on NF-??B through complex formation with PACT (PRKRA) and TRBP (TARBP2), driving pro-inflammatory gene expression. Additionally, PKR activates p38 MAPK, JNK, and caspase cascades, promoting apoptosis. Downstream effectors include ATF4, CHOP, GADD34, and PP1, which mediate adaptive or cell death outcomes.

In the context of CAL-27 oral cancer cells, EIF2AK2 knockout disrupts a key node linking dsRNA sensing and environmental stress to translational reprogramming and survival decisions. Given that head and neck squamous cell carcinomas frequently experience hypoxic, nutrient-deprived, and inflammatory stress, loss of PKR may alter tumor cell fitness, chemosensitivity, and immunogenic signaling. This knockout model enables dissection of PKR’s contributions to cancer cell-intrinsic stress tolerance, apoptotic threshold regulation, and potential crosstalk with oncogenic pathways.

Researchers can employ this polyclonal knockout population in diverse experimental workflows to investigate PKR biology. Representative assays include Western blotting for phospho-eIF2?? and total PKR to confirm signaling ablation, RT-qPCR profiling of interferon-stimulated gene expression, transcriptome-wide analysis via RNA-seq to identify PKR-dependent gene programs, and flow cytometric apoptosis detection with Annexin V. Co-immunoprecipitation experiments can probe PKR interactors such as PACT or viral protein antagonists, while phospho-signaling arrays enable mapping of affected kinase cascades. Drug sensitivity studies can explore PKR-dependent chemoresistance mechanisms. For further information or to discuss custom applications, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)